US vaccine panel upends hepatitis B advice in latest Trump-era shift – World

An advisory panel appointed by President Donald Trump’s vaccine-sceptic health secretary voted on Friday to stop recommending that all newborns in the United States receive a hepatitis B vaccine.

The move to end the decades-old recommendation is the panel’s latest contentious about-face on vaccine policy since its overhaul by Health Secretary Robert F. Kennedy Jr. earlier this year.

US health authorities previously recommended that all babies, not just those born to mothers believed to have hepatitis B, receive the first of three vaccine doses just after birth.

The approach aimed, in part, to prevent transfers from mothers who unknowingly had hepatitis B or had falsely tested negative, and had virtually eradicated infections of the potentially deadly liver disease among young people in the country.

After delaying the vote by a day, the panel on Friday passed its new recommendation for “individual-based decision-making,” in consultation with a health care provider, when children are born to mothers testing negatively for the disease.

The decision to vaccinate at birth should “consider vaccine benefits, vaccine risks, and infection risks”.

Trump hailed the move as “a very good decision” on his Truth Social platform.

But the new recommendation was immediately condemned by several medical groups, who noted widespread shortcomings in US maternal health screening as well as the possibility of infections from others.

“This irresponsible and purposely misleading guidance will lead to more hepatitis B infections in infants and children,” American Academy of Pediatrics President Susan J. Kressly said in a statement.

The vote was 8–3.

Trump-appointed officials at the Centres for Disease Control and Prevention (CDC) are expected to formally adopt the recommendations at a later date.

The panel also voted to recommend that babies who are not vaccinated at birth wait at least two months to get the initial dose, and that blood tests be done to measure antibodies before a second dose.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top